%0 Generic
%A B., Rack
%A E., Zombirt
%A E., Trapp
%A J., Jückstock
%A U., Andergassen
%A J., Neugebauer
%A B., Kost
%A T., Weissenbacher
%A U., Jeschke
%A C., Schindlbeck
%D 2016
%T Supplementary Material for: Comparison of HER2 Expression in Primary Tumor and Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients
%U https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Comparison_of_HER2_Expression_in_Primary_Tumor_and_Disseminated_Tumor_Cells_in_the_Bone_Marrow_of_Breast_Cancer_Patients/5129206
%R 10.6084/m9.figshare.5129206.v1
%2 https://karger.figshare.com/ndownloader/files/8717710
%K Breast cancer
%K Circulating tumor cells
%K Disseminated tumor cells
%K Minimal residual disease
%K HER2
%K Bone marrow
%K HER2-targeting agent
%X Objective: The aim of this study was to measure the human epidermal growth factor receptor 2 (HER2) status of disseminated tumor cells (DTCs) from bone marrow (BM) aspirates and to assess correspondence or discrepancy with the primary tumor. Methods: DTCs were isolated from the BM of 156 breast cancer patients. Cytokeratin-positive DTCs were further analyzed by the chromogenic in situ hybridization method to detect HER2 gene amplification. Results: A significant correlation (p = 0.021) was found between the HER2 status of DTCs and the primary tumors. Sixty-one (68.5%) patients had a corresponding status. However, a shift of phenotype between primary tumor and DTCs was found in the remaining patients. Conclusion: This study showed a significant grade of discordance of the HER2 status between primary tumors and DTCs in the BM of a relevant subgroup of patients. Detection of HER2 amplification on DTCs could therefore help to better stratify patients for a more tailored therapy, since they would benefit from a HER2-targeted therapy.
%I Karger Publishers